Tivic, The Feinstein Institutes for Medical Research Announce Pilot Study to Test Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation
13 Abril 2023 - 10:00AM
Business Wire
Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a
commercial-phase health technology company that develops and
commercializes bioelectronic medicine, today announced a research
collaboration with The Feinstein Institutes for Medical Research to
conduct a pilot clinical study that will test a novel non-invasive
bioelectronic device approach for vagus nerve stimulation.
“Establishing on- and off-target effects of non-invasive vagal
stimulation remains a major goal in the field of bioelectronic
medicine,” said Theodoros Zanos, Ph.D., associate professor in the
Institute of Bioelectronic Medicine at the Feinstein Institutes for
Medical Research. “Refinement of the strategies used to stimulate
the vagus nerve non-invasively could be an important step in
validating a novel approach to the treatment of autonomic
conditions. This study may provide greater targeting strategies of
stimulation and more control over the types of physiologic effects
that result from stimulation.”
The pilot study will utilize a new neurostimulation approach
with 20 individuals, along with data analysis and algorithm
development acquired from the Neural and Data Science Autonomic
Nervous System monitoring lab.
“The Feinstein Institutes is the internationally recognized
leader in pioneering bioelectronic medicine research,” said
Jennifer Ernst, CEO at Tivic. “We’re excited about this study
because it has the possibility for Tivic to expand our non-invasive
bioelectronic solutions from trigeminal and sympathetic nerve
stimulation to vagus nerve pathways and clinical uses. Dr. Blake
Gurfein, our Chief Scientific Officer, and Dr. Zanos are
neuroscience colleagues who believe this work could provide great
proprietary value.”
About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the home of the
research institutes of Northwell Health, the largest health care
provider and private employer in New York State. Encompassing 50
research labs, 3,000 clinical research studies and 5,000
researchers and staff, the Feinstein Institutes raises the standard
of medical innovation through its five institutes of behavioral
science, bioelectronic medicine, cancer, health system science, and
molecular medicine. We make breakthroughs in genetics, oncology,
brain research, mental health, autoimmunity, and are the global
scientific leader in bioelectronic medicine – a new field of
science that has the potential to revolutionize medicine. For more
information about how we produce knowledge to cure disease, visit
http://feinstein.northwell.edu and follow us on LinkedIn.
About Tivic
Tivic Health Systems, Inc. is a commercial-phase health
technology company delivering non-invasive bioelectronic treatments
that provide consumers with a choice in the treatment of
inflammation and certain other related conditions. For more
information visit https://tivichealth.com @TivicHealth.
Forward-Looking Statements
This press release may contain “forward-looking statements” that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
“will” “would,” or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on Tivic Health
Systems, Inc.’s current expectations and are subject to inherent
uncertainties, risks, and assumptions that are difficult to
predict. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Actual results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: market and other conditions; supply
chain constraints; macroeconomic factors; unexpected costs, charges
or expenses that reduce Tivic’s capital resources; and the
completion and success of the clinical study. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements. For a discussion of other risks
and uncertainties, and other important factors, any of which could
cause Tivic’s actual results to differ from those contained in the
forward-looking statements, see Tivic’s filings with the SEC,
including, its Annual Report on Form 10-K for the year ended
December 31, 2022, filed with the SEC on March 31, 2023, under the
heading “Risk Factors,” as well as the company’s subsequent filings
with the SEC. Forward-looking statements contained in this press
release are made as of this date, and Tivic Health Systems, Inc.
undertakes no duty to update such information except as required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230413005247/en/
Tivic Kayleigh Westerfield 949-632-3439
Kayleigh.Westerfield@tivichealth.com
Feinstein Institutes for Medical Research Matthew Libassi
631-793-5325 mlibassi@northwell.edu
Tivic Health Systems (NASDAQ:TIVC)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tivic Health Systems (NASDAQ:TIVC)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024